HypertensionKorHRNCT01861080
Korean Registry of Target Organ Damages in Hypertension
An observational study of Hypertension, run by Dongtan Sacred Heart Hospital at 1 site in South Korea.
Trial summary
The objective of this study is to know prevalence of clinical or subclinical target organ damages in Korea hypertensives by constructing nationwide hypertension registry. We will register 5000 consecutive patients with incident hypertension at 20 major university hospitals in South Korea. Read more about this study
- Who is it for?
- Ages 30 years and older
- Conditions the study is for
- Hypertension
- How many people
- 3,000 participants
- Where
- 1 siteSouth Korea
- Study dates
- 21 Dec 2012to 4 Apr 2025
- How long will I take part?
- 36 Months
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Korean patients with incident hypertensive, who visited university hospital
Who may be able to join
- age≧30years
- primary incident hypertension
- singed informed consent
Who cannot join
- participated in other clinical trials
Trial locations and contacts
1 site in 1 country.
South Korea1 site
Hallym University Dongtan Sacred Heart Hospital,
Hwaseong, Gyeonggido, 445-170
About this study
Official title: Observational Study of Clinical Characteristics and Prognostic Factors of Korean Hypertensives
The objective of this study is to know prevalence of clinical or subclinical target organ damages in Korea hypertensives by constructing nationwide hypertension registry. We will register 5000 consecutive patients with incident hypertension at 20 major university hospitals in South Korea. We will investigate clinical/subclinical target organ damages, renin/aldosterone level and cardiovascular events in each patient.
Read the detailed description
Background: the exact prevalence of target organ damages in Korean hypertensives are unknown.
Study Objective: to investigate the prevalence of target organ damages in Korean patients with incident hypertension.
Study Design: prospective, multi-center and observational study
Study Populaton: approximately 5000 consecutive patients with incident hypertension, who visited outpatients clinics and agreed to participate in the registry
Primary outcome
- Subclinical organ damages
- left ventricular hypertrophy on electrocardiogram or echocardiography
- increased intima media thickness of carotid artery (> 0.9 mm) or plaque
- increased pulse wave velocity (> 12 m/s)
- low estimated glomerular filtration rate (< 60 ml/min/1.73 m2) or creatinine clearance (<60 ml/min)
- Established CV or renal disease
- cerebrovascular disease: ischemic stroke; cerebral stroke; transient ischemic attack
- Heart disease: myocardial infarction; angina; coronary revascularization; heart failure
- Renal disease: diabetic retinopathy; serum creatinine M > 133, W > 124 mmol/L; proteinuria > 300 mg/24 hr
- Peripheral artery disease
- Advanced retinopathy: hemorrhage or exudates, papilledema
- Conditions
- Hypertension
- Keywords
- target organ damage, incident hypertension, cohort
- Medical subject headings
- Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| incident hypertensives | Inclusion Criteria: * age≧30years * primary incident hypertension * signed informed consent |
What is being measured
The primary outcome is the main question the study is designed to answer.
left ventricular hypertrophy
left ventricular hypertrophy on electrocardiogram or echocardiography Sokolow-Lyon > 38 mm; left ventricular mass index male >= 125 g/m2, female >=110 g/m2)
Measured: at enrollment
Intima media thickness of carotid artery
increased intima media thickness of carotid artery (> 0.9 mm) or presence of plaque
Measured: at enrollment
pulse wave velocity
increased pulse wave velocity (> 12 m/s)
Measured: at enrollment
kidney function
low estimated glomerular filtration rate (< 60 ml/min/1.73 m2) or creatinine clearance (< 60 ml/min)
Measured: at enrollment
cerebrovascular accident
ischemic stroke, cerebral hemorrhage, or transient ischemic attack confirmed by a neurologist
Measured: at enrollment
renal disease
serum creatinine male > 1.5 mg/dl, female > 1.4 mg/dl; proteinuria > 300 mg/24hr
Measured: at enrollment
peripheral artery disease
ankle to brachial blood pressure ratio < 0.9
Measured: at enrollment
retinopathy
retinal hemorrhage or exudate, papilledema confirmed by an ophthalmologist
Measured: at enrollment
Secondary outcomes (5)
Hypertension
high blood pressure confirmed by ambulatory blood pressure monitoring (24hr average systolic blood pressure >=135 mm Hg, diastolic blood pressure >= 85 mm Hg
Measured: at enrollment
Dyslipidemia
total cholesterol 190 mg/dl or LDL > 115 mg/dl, HDL male < 40 mg/dl, female < 46 mg/dl or triglyceride > 150 mg/dl
Measured: at enrollment
abnormal fasting plasma glucose
abnormal fasting plasma glucose (102-125 mg/dl)
Measured: at enrollment
abdominal obesity
waist circumference male > 102 cm, female > 88 cm
Measured: at enrollment
diabetes mellitus
fasting plasma glucose >= 126 mg/dl; postload plasma glucose > 198 mg/dl
Measured: at enrollment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 May 2013 (estimated)
- Study start21 Dec 2012
- Primary completion4 Apr 2025
- Study completion4 Apr 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for HypertensionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 3,000 participants (estimated)
- Target duration
- 36 Months
Sponsor and investigators
- Lead sponsor
- Dongtan Sacred Heart Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Kyu-Hyung Ryu, MD, PhD, Principal investigator, Dongtan Sacred Heart Hospital, Hallym University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01861080
- Sponsor's protocol ID
- 2012-005
- Acronym
- KorHR
- Status last verified
- Aug 2026
- First submitted
- 16 May 2013
- Last updated
- 26 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- Undecided
Publications
Kim DY, Kim SH, Han SW, Ok JS, Son JW, Jeong JO, Kim EJ, Choi S, Jung IH, Ryu SK, Shin MS, Ryu KH. Evaluation of guideline adherence to hypertension-mediated organ damage screening in Korean patients with hypertension: results from the Korean Registry of Target Organ Damage in Hypertension (KorHR). Clin Hypertens. 2026 Mar 1;32:e11. doi: 10.5646/ch.2026.32.e11. eCollection 2026.
PubMed 41799943Choi SW, Han SW, Ok JS, Yoo BS, Shin MS, Park SH, Ryu KH. A multicenter cohort study of primary hypertension in Korea: study design and interim analysis of the Korean registry of target organ damage in hypertension (KorHR). Clin Hypertens. 2017 Aug 2;23:16. doi: 10.1186/s40885-017-0072-2. eCollection 2017.
PubMed 28794898
Study at a glance
From the registry record, last updated by the sponsor on 26 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Observational Study of Clinical Characteristics and Prognostic Factors of Korean Hypertensives
- ClinicalTrials.gov ID
- NCT01861080
- Acronym / sponsor ID
- KorHR / 2012-005
- Conditions
- Hypertension
- Keywords
- target organ damage, incident hypertension, cohort
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 3,000 participants (estimated)
- Lead sponsor
- Dongtan Sacred Heart HospitalUniversity, hospital or other
- Study start
- 21 Dec 2012 (actual)
- Primary completion
- 4 Apr 2025 (actual)
- Study completion
- 4 Apr 2025 (actual)
- First posted
- 23 May 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study is to know prevalence of clinical or subclinical target organ damages in Korea hypertensives by constructing nationwide hypertension registry. We will register 5000 consecutive patients with incident hypertension at 20 major university hospitals in South Korea. We will investigate clinical/subclinical target organ damages, renin/aldosterone level and cardiovascular events in each patient.
Detailed description
Background: the exact prevalence of target organ damages in Korean hypertensives are unknown.
Study Objective: to investigate the prevalence of target organ damages in Korean patients with incident hypertension.
Study Design: prospective, multi-center and observational study
Study Populaton: approximately 5000 consecutive patients with incident hypertension, who visited outpatients clinics and agreed to participate in the registry
Primary outcome
- Subclinical organ damages
- left ventricular hypertrophy on electrocardiogram or echocardiography
- increased intima media thickness of carotid artery (> 0.9 mm) or plaque
- increased pulse wave velocity (> 12 m/s)
- low estimated glomerular filtration rate (< 60 ml/min/1.73 m2) or creatinine clearance (<60 ml/min)
- Established CV or renal disease
- cerebrovascular disease: ischemic stroke; cerebral stroke; transient ischemic attack
- Heart disease: myocardial infarction; angina; coronary revascularization; heart failure
- Renal disease: diabetic retinopathy; serum creatinine M > 133, W > 124 mmol/L; proteinuria > 300 mg/24 hr
- Peripheral artery disease
- Advanced retinopathy: hemorrhage or exudates, papilledema
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 36 Months
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| incident hypertensives | – | –Inclusion Criteria: * age≧30years * primary incident hypertension * signed informed consent |
Who may qualify
- Ages
- 30 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Korean patients with incident hypertensive, who visited university hospital
Key inclusion criteria (3 listed)
- age≧30years
- primary incident hypertension
- singed informed consent
Key exclusion criteria (1 listed)
- participated in other clinical trials
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
left ventricular hypertrophy
Time frame: at enrollment
left ventricular hypertrophy on electrocardiogram or echocardiography Sokolow-Lyon > 38 mm; left ventricular mass index male >= 125 g/m2, female >=110 g/m2)
Intima media thickness of carotid artery
Time frame: at enrollment
increased intima media thickness of carotid artery (> 0.9 mm) or presence of plaque
pulse wave velocity
Time frame: at enrollment
increased pulse wave velocity (> 12 m/s)
kidney function
Time frame: at enrollment
low estimated glomerular filtration rate (< 60 ml/min/1.73 m2) or creatinine clearance (< 60 ml/min)
cerebrovascular accident
Time frame: at enrollment
ischemic stroke, cerebral hemorrhage, or transient ischemic attack confirmed by a neurologist
renal disease
Time frame: at enrollment
serum creatinine male > 1.5 mg/dl, female > 1.4 mg/dl; proteinuria > 300 mg/24hr
peripheral artery disease
Time frame: at enrollment
ankle to brachial blood pressure ratio < 0.9
retinopathy
Time frame: at enrollment
retinal hemorrhage or exudate, papilledema confirmed by an ophthalmologist
5 secondary outcomes
Hypertension
Time frame: at enrollment
Dyslipidemia
Time frame: at enrollment
abnormal fasting plasma glucose
Time frame: at enrollment
abdominal obesity
Time frame: at enrollment
diabetes mellitus
Time frame: at enrollment
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Aug 2026.
- Derived from this study: PubMed 41799943Kim DY, Kim SH, Han SW, Ok JS, Son JW, Jeong JO, Kim EJ, Choi S, Jung IH, Ryu SK, Shin MS, Ryu KH. Evaluation of guideline adherence to hypertension-mediated organ damage screening in Korean patients with hypertension: results from the Korean Registry of Target Organ Damage in Hypertension (KorHR). Clin Hypertens. 2026 Mar 1;32:e11. doi: 10.5646/ch.2026.32.e11. eCollection 2026.
- Derived from this study: PubMed 28794898Choi SW, Han SW, Ok JS, Yoo BS, Shin MS, Park SH, Ryu KH. A multicenter cohort study of primary hypertension in Korea: study design and interim analysis of the Korean registry of target organ damage in hypertension (KorHR). Clin Hypertens. 2017 Aug 2;23:16. doi: 10.1186/s40885-017-0072-2. eCollection 2017.
- Individual participant dataSharing planned: Undecided
Related trials for Hypertension
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Enrolling by invitation
Testing Implementation Strategies to Support Clinic Fidelity to an Outpatient Hypertension Bundle
Pregnancy Related, Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kyu-Hyung Ryu, MD, PhD principal investigator
Dongtan Sacred Heart Hospital, Hallym University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hypertension, run by Dongtan Sacred Heart Hospital at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
left ventricular hypertrophy (time frame: at enrollment). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01861080, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Aug 2026.